Danaher Corporation vs Huntington Bancshares Incorporated — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Huntington Bancshares Incorporated trades at $15.32 (market cap $31.04B). The key difference: Danaher Corporation is far larger — about 4.9× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (4.04%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Huntington Bancshares Incorporated for 52 Days on average.
| DHR | HBAN | |
|---|---|---|
Market Cap | $152.87B | $31.04B |
Volume | 5,228,698 | 23,864,172 |
Sector | Health | Financials |
52-Week High | $242.05 | $19.27 |
52-Week Low | $161.91 | $15.02 |
Typical Hold Time | 69 Days | 52 Days |
Enterprise Value | $175.08B | $49.57B |
Dividend Yield | 0.74% | 4.04% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Huntington Bancshares (HBAN) trades at $15.37, up 1.32% today, but faces a bearish technical outlook with support at $15 and resistance at $16. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026, with Q3 2026 results pending. Revenue grew to $8.13B in 2025, and the stock trades at a P/E of 11.82, below the industry average, while analyst sentiment is split with a consensus price target of $19.60.
HBAN offers value with solid profitability and shareholder returns via dividends and buybacks, but near-term headwinds include interest rate pressures, margin compression, and lowered 2027 guidance. Risks involve economic sensitivity and competitive lending markets, yet institutional interest remains with significant holdings. The stock presents a cautious opportunity for value investors amid volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →